medigraphic.com
ISSN 1561-3011 (Electronic)

2016, Number 1

Next >>

Rev Cubana Invest Bioméd 2016; 35 (1)

Pleural mesothelioma and asbestos exposure in Spain

Gea-Izquierdo E

Language: Spanish
References: 71
Page: 1-17
PDF size: 134.01 Kb.


ABSTRACT

Introduction: Asbestos is a mineral that showed to be carcinogenic. For decades it has been used in Spain in several industrial activities. Additionally, Spanish rules have been adopted for the storage, transport, labeling, control of the occupational environment and personal protective equipments.
Objectives: Analyze the epidemiology, prognosis, treatment and prevention of pleural mesothelioma from exposure to asbestos in Spain.
Methods: Descriptive study based on the review of the state of pleural mesothelioma in Spain. A bibliographic review and documentary analysis of the causal agent (asbestos) and pleural mesothelioma was done.
Results: Procedures for the control of environmental pollution and health protection was determined, along with the implementation of collective and individual protection measures in relation to the exposure and the risk of pollution linked to the agent.
Conclusions: The elimination of sources of the agent and health surveillance should be preventive tools against the development of the disease. The promotion and implementation of regulations that impose strict principles of banning, use or exposure to asbestos is required.


REFERENCES

  1. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the north-western Cape province. Br J Ind Med. 1960;17:260-71.

  2. Ewing WM, Spain WH, Clay EM, Bosserman FC. Variety of asbestos uses requires many different substitute materials. Occup Health Saf. 1985;54(5):42-7.

  3. Baan RA, Grosse Y. Man-Made Mineral (Vitreous) Fibres: Evaluations of Cancer Hazards by the IARC Monographs Programme. Mutat Res. 2004;553:43-58.

  4. Organización Panamericana de la Salud. Organización Mundial de la Salud. Clasificación Internacional de Enfermedades para Oncología. 3ª ed. Washington DC: OPS; 2003.

  5. Jones RD, Smith DM, Thomas PG. Mesothelioma in Great Britain in 1968-1983. Scand J Work Environ Health. 1988;14:145-52.

  6. López-Abente G, Hernández Barrera V, Pollán M, Aragonés N, Pérez Gómez B. Municipal pleural cancer mortality in Spain. Occup Environ Med. 2005;62:195-9.

  7. Boffetta P, Kogevinas M. Occupational cancer in Europe. Environ Health Perspect. 1999;107(2):227.

  8. Gardner MJ, Saracci R. Effects on health of non-occupational exposure to airborne mineral fibres. En: Bignon J, Peto J, Saracci R, editores. Non-occupational exposure to mineral fibres. Lyon: IARC Sci. Publ. 1989;375-97.

  9. Howell D, Arblaster L, Swinburne L, Schweiger M, Renvoize E, Hatton P, et al. Routes of asbestos exposure and the development of mesothelioma in an English region. Occup Environ Med. 1997;54:403-9.

  10. Mollo F, Magnani C. European multicentric case control study on risk for mesothelioma after non-occupational (domestic and environmental) exposure to asbestos. Med Lav. 1995;86(5):496-500.

  11. Agudo A, Gonzalez CA, Bleda MJ, Ramirez J, Hernandez S, Lopez F, et al. Occupation and risk of malignant pleural mesothelioma: A case-control study in Spain. Am J Ind Med. 2000;37(2):159-68.

  12. Peto J. Fibre carcinogenesis and environmental hazards. En: Bignon J, Peto J, Saracci R, editores. Non-occupational exposure to mineral fibres. IARC Scientific Publications Nº 90. Lyon: International Agency for Research on Cancer. 1989;457- 70.

  13. Krakowiak E, Górny RL, Cembrzynska J, Sakol G, Boissier Draghi M, Anczyk E, et al. Environmental exposure to airborne asbestos fibres in a highly urbanized city. Ann Agric Environ Med. 2009;16:121-8.

  14. Magnani C, Agudo A, González CA, Andrion A, Calleja A, Chellini E, et al. Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Br J Cancer. 2000;83(1):104-11.

  15. Strickler HD, Goedert JJ, Devesa SS, Lahey J, Fraumeni JF, Rosenberg PS, et al. Trends in US pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst. 2003;95:38-45.

  16. Robledo R, Mossman B. Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cell Physiol. 1999;180:158-66.

  17. Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax. 1999;54(7):638-52.

  18. Marchi E, Liu W, Broaddus VC. Mesothelial cell apoptosis is confirmed in vivo by morphological change in cytokeratin distribution. Am J Physiol Lung Cell Mol Physiol. 2000;278:528-35.

  19. Battifora H, McCaughey WTE. Tumors of the serosal membranes. En: Rosai J, Sobin LH, editores. Atlas of Tumor Pathology. Third Series, Fascicle 15. Washington, DC, Armed Forces Institute of Pathology; 1995. p. 17-99.

  20. Metintas M, Hillerdal G, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J. 1999;13(3):523-6.

  21. Ismail Khan R, Robinson LA, Williams CC, Garrett CR, Bepler G, Simon GR, et al. Malignant Pleural Mesothelioma: A Comprehensive Review. Cancer Control. 2006;13(4):255-63.

  22. Morgan A, Holmes A. Concentrations and characteristics of amphibole fibres in the lungs of workers exposed to crocidolite in the British gas-mask factories, and elsewhere, during the second world war. Br J Ind Med. 1982;39(1):62-9.

  23. McDonald JC, Harris J, Berry G. Sixty years on: the price of assembling military gas masks in 1940. Occup Environ Med. 2006;63(12):852-5.

  24. Abu Shams K, Pascal I. Asbestos: characteristics, properties, pathogenesis and sources of exposure. An Sist Sanit Navar. 2005;28(1):7-11.

  25. Suzuki Y, Yuen SR. Asbestos fibers contributing to the induction of human malignant mesothelioma. Ann NY Acad Sci. 2002;982:160-76.

  26. Testa JR, Pass HI, Carbone M. Molecular Biology of Mesothelioma. En: De Vita V, Hellman S, Rosenberg S, Williams & Wilkins (eds). Principles and Practice of Oncology. Philadelphia PA: Lippincott. 2001;1937-43.

  27. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157:1666-80.

  28. Neri M, Filiberti R, Taioli E, Garte S, Paracchini V, Bolognesi C, et al. Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutat Res. 2005;592:36-44.

  29. Case Records of the Massachusetts General Hospital (case 33111). N Engl J Med. 1947;236:407-12.

  30. Doll R. Mortality from lung cancer in asbestos workers. Br J Ind Med. 1955;12:81-6.

  31. Hansen J, Klerk N, Musk A, Hobbs M. Environmental Exposure to Crocidolite and Mesothelioma. Am J Resp Crit Care Med. 1998;157:69-75.

  32. Encuentra AL, Simó GV, Rodríguez TS. Mesoteliomas pleurales malignos. Descripción de 23 casos con análisis de supervivencia. Rev Clin Esp. 1987;181:496- 502.

  33. NIOSH. The Work-Related Lung Disease Surveillance Report 2002. Publication No. 2003-111. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Division of Respiratory Disease Studies, Surveillance Branch. 2002 [Citado 28 de septiembre de 2015]. Disponible en: http://www.cdc.gov/niosh/docs/2003-111/pdfs/2003-111.pdf

  34. Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004;125:1103-17.

  35. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666-72.

  36. McElvenny D, Darnton A, Price M, Hodgson JT. Mesothelioma mortality in Great Britain from 1968 to 2001. Occup Med. 2005;55:79-87.

  37. Montanaro F, Bray F, Gennaro V, Merler E, Tyczynski JE, Parkin DM, et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control. 2003;14:791-803.

  38. Bianchi C, Bianchi T. Malignant mesothelioma: Global incidence and relationship with asbestos. Ind Health. 2007;45:379-87.

  39. Sluis Kremer GK. Asbestos disease at low exposures after long residence times. Ann NY Acad Sci. 1991;643:182-93.

  40. López-Abente G, Pollán M, Escolar A, Errezola M, Abraira V. Atlas de mortalidad por cáncer y otras causas en España, 1978-1992. Madrid: Instituto de Salud Carlos III; 2001.

  41. Grupo de Estudio del Mesotelioma en Barcelona (GEMEBA). Mortalidad por mesotelioma pleural en la provincia de Barcelona. Med Clin (Barc). 1993;101:565- 9.

  42. Tarrés J, Abós Herràndiz R, Albertí C, Martínez Artés X, Rosell Murphy M, García Allas I, et al. Asbestos-related diseases in a population near a fibrous cement factory. Arch Bronconeumol. 2009;45(9):429-34.

  43. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer Incidence in Five Continents, Vol. IX. IARC Scientific Publications No. 160. Lyon: IARC; 2007.

  44. Kjaergaard J, Anderson M. Incidence rates of malignant mesothelioma in Denmark and predicted future number of cases among men. Scand J Work Environ Health. 2000;26:112-7.

  45. Mowe G, Gylseth B, Hartveit F, Skaug V. Occupational asbestos exposure, lungfiber concentration and latency time in malignant mesothelioma. Scand J Work Environ Health. 1984;10:293-8.

  46. Solomons K. Malignant mesothelioma: clinical and epidemiological features. A report of 80 cases. S Afr Med J. 1984;66:407-12.

  47. Banaei A, Auvert B, Goldberg M, Gueguen A, Luce D, Goldberg S, et al. Future trends in mortality of French men from mesothelioma. Occup Environ Med. 2000;57(7):488-94.

  48. Pitarque S, Cleries R, Martinez JM, Lopez-Abente G, Kogevinas M, Benavides FG, et al. Mesothelioma mortality in men: trends during 1977-2001 and projections for 2002-2016 in Spain. Occup Environ Med. 2008;65(4):279-82.

  49. Fraumeni JF, Blot WJ. Lung and pleura. En: Schottenfeld D, Fraumeni JF, editores. Cancer epidemiology and prevention. Filadelfia: Saunders; 1982. p. 576- 82.

  50. Peto J, Doll R, Hermon C, Binns W, Clayton R, Goffe T, et al. Relationship of mortality to measures of environmental asbestos pollution in an asbestos textile factory. Ann Occup Hyg. 1985;29:305-55.

  51. Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E, et al. Mesothelioma epidemic in Western Europe: an update. Br J Cancer. 2004;90:1022-4.

  52. Martínez C, Monsó E, Quero A. Emerging Pleuropulmonary Diseases Associated With Asbestos Inhalation. Arch Bronconeumol. 2004;40:166-77.

  53. Isidro I, Abu Shams K, Alday E, Carretero JL, Ferrer J, Freixa A, et al. Guidelines on asbestos-related pleuropulmonary disease. Arch Bronconeumol. 2005;41(3):153-68.

  54. Lin Chu M, Lee YJ, Ho MY. Malignant mesothelioma in infancy. Arch Pathol Lab Meth. 1989;113(4):409-11.

  55. Dazzi H, Thatcher N, Hasleton PS, Chatterjee AK, Lawson RAM. DNA analysis by flow cytometry in malignant pleural mesothelioma: relationship to histology and survival. J Pathol. 1990;162:51-5.

  56. Begin R, Gauthier JJ, Desmeules M, Ostiguy G. Work-related mesothelioma in Québec, 1967-1990. Am J In Med. 1992;22(4):531-42.

  57. Dawson A, Gibbs AR, Pooley FD, Griffiths DM, Hoy J. Malignant mesothelioma in women. Thorax. 1993;48:269-74.

  58. Rosenthal GJ, Simeonova P, Corsini E. Asbestos toxicity: An immunologic perspective. Rev Environ Health. 1999;14:11-20.

  59. Fernández Infante B, Michel FJ. Malign pleural mesothelioma. Anales Sis San Navarra. 2005;28(1):29-35.

  60. Kogevinas M, Maqueda J, De la Orden V, Fernández Gómez F, Kauppinen T, Benavides FG, et al. Exposición a carcinógenos laborales en España: aplicación de la base de datos CAREX. Arch Prev Riesgos Labor. 2000;3(4):153-9.

  61. Talcott J, Thurber W, Gaensler E, Antman K, Li FP. Mesothelioma in manufacturers of asbestos-containing cigarette filters. Lancet. 1987;1(8529):392.

  62. Rogers AJ, Leigh J, Berry G, Ferguson DA, Mulder HB, Ackad M, et al. Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma. Cancer. 1991;67(7):1912-20.

  63. Directiva 91/659/CEE. Anexo I de la Directiva 76/769/CEE del Consejo relativa a la aproximación de las disposiciones legales, reglamentarias y administrativas de los Estados miembros que limitan la comercialización y el uso de determinadas sustancias y preparados peligrosos (amianto). DOUE. 31 Dic 1991;363:36-8.

  64. Directiva 1999/77/CE de la Comisión. Anexo I de la Directiva 76/769/CEE del Consejo relativa a la aproximación de las disposiciones legales, reglamentarias y administrativas de los Estados miembros que limitan la comercialización y el uso de determinadas sustancias y preparados peligrosos (amianto). DOUE. 6 Ago 1999;207:18-20.

  65. Orden de 7 de diciembre de 2001 por la que se modifica el anexo I del Real Decreto 1406/1989, de 10 de noviembre, por el que se imponen limitaciones a la comercialización y al uso de ciertas sustancias y preparados peligrosos. BOE. 14 Dic 2001;299:47156-7.

  66. Real Decreto 396/2006, de 31 de marzo, por el que se establecen las disposiciones mínimas de seguridad y salud aplicables a los trabajos con riesgo de exposición a amianto. BOE. 11 Abr 2006;86:13961-74.

  67. Goldberg M, Luce D. Can Exposure to Very Low Levels of Asbestos Induce Pleural Mesothelioma?. Am J Respir Crit Care Med. 2005;172:939-40.

  68. Ministerio de Empleo y Seguridad Social. Instituto Nacional de Seguridad e Higiene en el Trabajo. Límites de Exposición Profesional para Agentes Químicos en España. Madrid; 2012.

  69. Merler E, Buiatti E, Vainio H. Surveillance and intervention studies on respiratory cancers in asbestos-exposed workers. Scand J Work Environ Health. 1997;23(2):83-92.

  70. Franqués L, Badia X, Benavides FG, Rajmil L, Segura A. The incidence of occupational diseases: a study of medical evaluations for incapacity in Barcelona (1987-1991). Med Clin. 1995;18(10):361-4.

  71. Pujolar AE, Gonzalez C, Agudo A, Calleja A, Beltran M, Gonzalez Moya J, et al. Information about occupational exposure to asbestos given to cases in an etiological study: ethical aspects. Eur J Epidemiol. 2001;17(1):1-6.




2020     |     www.medigraphic.com